A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQH3906 Capsules in Healthy Volunteers
Latest Information Update: 08 Mar 2024
At a glance
- Drugs TQH 3906 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 01 Mar 2024 Status changed from not yet recruiting to recruiting.
- 05 Feb 2024 New trial record